Intra-abdominal infection (IAI) is a broad term that encompasses a number of infectious processes, including peritonitis, diverticulitis, cholecystitis, cholangitis, and pancreatitis. A common cause of IAI is appendicitis. Two classifications are used to subdivide IAIs: uncomplicated or complicated, considering infection extent; and community-acquired, healthcare-associated or hospital-acquired, regarding the place of acquisition.
The organism responsible for the IAI can be inferred based on the location of the organ originally infected since the resident GI flora is typically the culprit in the IAI. Early prognostic evaluation of complicated intra-abdominal infections is important to assess the severity and the prognosis of the disease.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/complicated-intra-abdominal-infections-market
The Complicated Intra-Abdominal Infections Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Complicated Intra-Abdominal Infections market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Complicated Intra-Abdominal Infections treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Complicated Intra-Abdominal Infections Market Key Facts
-
As per the study by Sartelli et al. (2013) titled “Complicated intra-abdominal infections in a worldwide context: an observational prospective study (CIAOW Study)”, out of total selected patients, 38.7% patients were women and 62.3% were men. Among these patients, 87.6% were affected by community-acquired IAIs while the remaining 12.4% suffered from healthcare-associated infections.
-
As per the study conducted by Chong, et al. (2014), patients hospitalized for community-onset cIAI were included in the analysis. The most common intra-abdominal diagnosis was complicated appendicitis (52%), followed by perforation of the intestine (17%), and perforated duodenal ulcer (16%).
-
As per the study by Labricciosa et al. (2018), a total of 4040 cIAIs were recorded; among them, 92.1% had a CA-cIAI versus 7.9% who had a HA-cIAI.
-
As per the study by Zhang, et al. (2015), the pathogens collected from IAI cases mainly consisted of gram-negative bacteria, which were found in 53.0% of mild-moderate CIAIs, 48.8% of severe CIAIs. Gram-positive was found in 16.7% in mild to moderate cIAI and 21.7% in severe cIAIs.
Key Benefits of Complicated Intra-Abdominal Infections Market Report
-
Complicated Intra-Abdominal Infections market report provides an in-depth analysis of Complicated Intra-Abdominal Infections Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Complicated Intra-Abdominal Infections Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers the Complicated Intra-Abdominal Infections current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Complicated Intra-Abdominal Infections market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stages products, and other factors.
Complicated Intra-Abdominal Infections Market
Complicated Intra-Abdominal Infections market size is expected to increase during the forecast period owing to the expected launch of emerging therapies.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Complicated Intra-Abdominal Infections market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Complicated Intra-Abdominal Infections market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Complicated Intra-Abdominal Infections Epidemiology
The epidemiology section covers insights about the historical and current Complicated Intra-Abdominal Infections patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Complicated Intra-Abdominal Infections Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Complicated Intra-Abdominal Infections market or expected to get launched in the market during the study period. The analysis covers Complicated Intra-Abdominal Infections market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Complicated Intra-Abdominal Infections Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Complicated Intra-Abdominal Infections market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Complicated Intra-Abdominal Infections emerging therapies.
The dynamics of the Complicated Intra-abdominal Infections (cIAI) market is anticipated to change in the coming years owing to the improvement in healthcare spending across the world. At present some of the major players at the global level are involved in the therapeutics development for the Complicated Intra-abdominal Infections (cIAI).
Request for Sample @ Complicated Intra-Abdominal Infections Therapeutics Market Assessment
Key Companies in the Complicated Intra-Abdominal Infections Market
-
Merck
-
Iterum Therapeutics
-
Verastem Oncology
And others
Complicated Intra-Abdominal Infections Therapies covered in the report include:
-
Sulopenem is an orally bioavailable, broad-spectrum penem β-lactam antibiotic that is being developed for the treatment of infections caused by multi-drug resistant bacteria.
-
Xerava (eravacycline) is a novel, fully synthetic, broad-spectrum parenteral antibiotic of the tetracycline class that has shown broadly in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug resistance (MDR) and are prevalent in China.
Table of Content
1. Key Insights
2. Executive Summary
3. Complicated Intra-Abdominal Infections Competitive Intelligence Analysis
4. Complicated Intra-Abdominal Infections Market Overview at a Glance
5. Complicated Intra-Abdominal Infections Disease Background and Overview
6. Complicated Intra-Abdominal Infections Patient Journey
7. Complicated Intra-Abdominal Infections Epidemiology and Patient Population
8. Complicated Intra-Abdominal Infections Treatment Algorithm, Current Treatment, and Medical Practices
9. Complicated Intra-Abdominal Infections Unmet Needs
10. Key Endpoints of Complicated Intra-Abdominal Infections Treatment
11. Complicated Intra-Abdominal Infections Marketed Products
12. Complicated Intra-Abdominal Infections Emerging Therapies
13. Complicated Intra-Abdominal Infections Seven Major Market Analysis
14. Attribute Analysis
15. Complicated Intra-Abdominal Infections Market Outlook (7 major markets)
16. Complicated Intra-Abdominal Infections Access and Reimbursement Overview
17. KOL Views on the Complicated Intra-Abdominal Infections Market.
18. Complicated Intra-Abdominal Infections Market Drivers
19. Complicated Intra-Abdominal Infections Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/complicated-intra-abdominal-infections-market
Latest Reports By DelveInsight
Complicated Intra-Abdominal Infections Pipeline Insights
Complicated Intra-Abdominal Infections Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across Complicated Intra-Abdominal Infections Market.
DelveInsight’s “Throat Cancer Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Throat Cancer market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/